European Union Approves Higher 7.2 mg Wegovy Dose for Enhanced Weight Loss

The European Union has approved an additional higher 7.2 mg maintenance dose option for Wegovy (semaglutide), a once-weekly GLP-1 receptor agonist for chronic weight management. This higher dose is intended as a step-up strategy after tolerance and response to standard 2.4 mg dosing, not as a starting dose, providing clinicians across EU countries with a higher maintenance dose pathway for selected patients.

The European Commission approved Wegovy 7.2 mg in February 2026, following the European Medicines Agency committee's positive scientific opinion issued in late 2025. The approval expands the ceiling of semaglutide dosing for obesity in the EU, offering an on-label option for patients with inadequate response at 2.4 mg despite good adherence.

Clinical trial data from the STEP UP Phase 3b study showed mean weight loss of about 20–21% with semaglutide 7.2 mg, compared with about 17–18% with 2.4 mg, and about 2–3% with placebo. The 7.2 mg dose produced a clear additional average weight-loss benefit over 2.4 mg, consistent with a dose-response effect, with many participants achieving large categorical losses including substantial proportions reaching ≥15–20% weight reduction.

The safety profile was generally consistent with known semaglutide effects, with gastrointestinal side effects remaining the most common. Some patients will not tolerate escalation, and careful titration and monitoring are important, with escalation typically reserved for those doing well on 2.4 mg but not reaching goals.

In the evidence base and early roll-out descriptions, 7.2 mg weekly can be delivered as three 2.4 mg injections administered in the same weekly session where a dedicated 7.2 mg single-injection pen is not yet available. The clinical approach treats 7.2 mg as an optional maintenance "next step" after 2.4 mg, rather than replacing the standard titration pathway.

Semaglutide is an FDA-approved prescription medication initially developed to treat type 2 diabetes that has shown remarkable results for weight management at higher doses. As a GLP-1 receptor agonist, it works by curbing hunger and reducing cravings, slowing stomach emptying for prolonged satiety after meals, and promoting better blood sugar balance for individuals with metabolic-related conditions.

GLP-1 medications have become a significant part of prescription spending for employers, with over half of employers now citing GLP-1s as a top driver of rising drug costs. A recent survey found that 68% of GLP-1 users said cost influenced their decision to start or continue treatment, and among those who stopped taking the medication, cost was the most common reason, even more than side effects or reaching a weight goal.